Immune Checkpoint Inhibitor-Related Adverse Effects and 18F-FDG PET/CT Findings

Basit Öğe Kaydı
dc.authoridSarikaya, Ismet/0000-0002-1087-580X
dc.authoridSchierz, Jan-Henning/0000-0002-6517-6029
dc.authorwosidSarikaya, Ismet/G-7881-2015
dc.authorwosidSchierz, Jan-Henning/AAC-1692-2022
dc.contributor.authorSchierz, Jan-Henning
dc.contributor.authorSarikaya, Ismet
dc.contributor.authorWollina, Uwe
dc.contributor.authorUnger, Leonore
dc.contributor.authorSarikaya, Ali
dc.date.accessioned2024-06-12T11:07:08Z
dc.date.available2024-06-12T11:07:08Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractImmune checkpoint inhibitor (ICI) treatments activate T cells against tumors. Activated T cells attack not only the tumor but also healthy cells, causing an autoimmune reaction in various tissues. These immune-related adverse effects (IRAEs) cause F-18-FDG uptake in various tissues due to inflammation. It is important to recognize and report these findings on F-18-FDG PET/CT studies. F-18-FDG PET helps to determine the presence, location, and severity of IRAEs. In severe cases, ICI treatments are interrupted or suspended and antiinflammatory treatments are started. F-18-FDG uptake due to IRAEs may mimic metastases or disease progression. Their presence may also help in predicting response to treatment and have prognostic implications. In this review article, we provide basic information about ICI treatments, IRAEs, and F-18-FDG PET/CT findings.en_US
dc.identifier.doi10.2967/jnmt.121.262151
dc.identifier.endpage329en_US
dc.identifier.issn0091-4916
dc.identifier.issn1535-5675
dc.identifier.issue4en_US
dc.identifier.pmid34330805en_US
dc.identifier.scopus2-s2.0-85121691008en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage324en_US
dc.identifier.urihttps://doi.org/10.2967/jnmt.121.262151
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21916
dc.identifier.volume49en_US
dc.identifier.wosWOS:000729242100007en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSoc Nuclear Medicine Incen_US
dc.relation.ispartofJournal Of Nuclear Medicine Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectF-18-FDG PET/CTen_US
dc.subjectAdverse Effecten_US
dc.subjectAutoimmuneen_US
dc.subjectBlood-Poolen_US
dc.subjectEventsen_US
dc.subjectMelanomaen_US
dc.subjectTomographyen_US
dc.subjectLiveren_US
dc.titleImmune Checkpoint Inhibitor-Related Adverse Effects and 18F-FDG PET/CT Findingsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu